BDTX
NASDAQ · Biotechnology
Black Diamond Therapeutics I
$2.11
+0.08 (+3.94%)
Open$2.05
Previous Close$2.03
Day High$2.14
Day Low$2.05
52W High$4.94
52W Low$1.20
Volume—
Avg Volume542.2K
Market Cap122.03M
P/E Ratio5.46
EPS$0.38
SectorBiotechnology
Analyst Ratings
Strong Buy
15 analysts
Price Target
+1,602.4% upside
Current
$2.11
$2.11
Target
$35.92
$35.92
$30.62
$35.92 avg
$44.24
Key Financials
| FY 2026 | FY 2025 | FY 2024 | |
|---|---|---|---|
| Revenue | 67.76M | 26.85M | 24.30M |
| Net Income | 21.65M | 2.09M | 2.49M |
| Profit Margin | 32.0% | 7.8% | 10.3% |
| EBITDA | 18.04M | 3.87M | 3.57M |
| Free Cash Flow | — | 2.98M | 2.09M |
| Rev Growth | — | +10.3% | +9.4% |
| Debt/Equity | — | 0.41 | 0.35 |
Biotechnology Peers
| Symbol | Name | Price | Change | P/E | Mkt Cap |
|---|---|---|---|---|---|
| ABBV | Abbvie Inc | $214.87 | -1.20% | 166.6 | 397.77B |
| AMGN | Amgen Inc | $354.05 | +0.63% | 24.7 | 190.40B |
| GILD | Gilead Sciences Inc | $140.73 | +0.98% | 19.6 | 166.66B |
| VRTX | Vertex Pharmaceuticals Inc | $449.71 | +0.71% | 29.1 | 114.87B |
| REGN | Regeneron Pharmaceuticals | $776.21 | +0.46% | 17.9 | 80.50B |
| ALNY | Alnylam Pharmaceuticals Inc | $330.87 | +4.68% | 139.7 | 43.84B |